DK2268142T3 - Anvendelse af alginerede oligomerer til at bekæmpe biofilm - Google Patents
Anvendelse af alginerede oligomerer til at bekæmpe biofilm Download PDFInfo
- Publication number
- DK2268142T3 DK2268142T3 DK08875658.0T DK08875658T DK2268142T3 DK 2268142 T3 DK2268142 T3 DK 2268142T3 DK 08875658 T DK08875658 T DK 08875658T DK 2268142 T3 DK2268142 T3 DK 2268142T3
- Authority
- DK
- Denmark
- Prior art keywords
- biofilm
- alginate oligomer
- alginate
- treatment
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A01N43/14—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
- A01N43/16—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/03—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21036—Pancreatic elastase (3.4.21.36)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pest Control & Pesticides (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Virology (AREA)
- Alternative & Traditional Medicine (AREA)
Claims (18)
1. Fremgangsmåde til at bekæmpe biofilm, der ikke er i eller på et humant eller ikke-humant dyrelegeme, hvilken fremgangsmåde omfatter at bringe biofilmen i kontakt med en alginatoligomer, hvor alginatoligomeren har mindst 70 % G-rester.
2. Fremgangsmåden ifølge krav 1, hvor biofilmen er på en ikke-levende overflade.
3. Fremgangsmåden ifølge krav 1 eller krav 2, hvor biofilmen er på en overflade valgt fra overflader til fødevare- eller drikkevarebehandling, -tilberedning, -opbevaring eller dispenseringsmaskineri eller -udstyr, overflader af luftkonditioneringsapparat, overflader af industrielt maskineri, overflader af opbevaringstanke, overflader af medicinsk eller kirurgisk udstyr, overflader af vand-/marineudstyr eller overfladerne af bygninger og andre strukturer, og fortrinsvis hvor overfladen vælges fra fødevarebehandlings-, opbevarings-, dispenserings eller tilberedningsudstyr eller overflader, tanke, transportbånd, gulve, afløb, kølere, frysere, udstyrsoverflader, vægge, ventiler, bælter, rør, luftkonditioneringsledninger, køleapparater, fødevare- eller drikkevare-dispenseringslinjer, varmevekslere, skibsskrog, dentalvandlinjer, olieboringsledninger, kontaktlinser, kontaktlinse-opbevaringsetui, katetre, proteser eller implanterbare medicinske indretninger.
4. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 3, hvor alginatoligomeren (i) har en gennemsnitsmolekylevægt på mindre end 35.000 Daltons, fortrinsvis mindre end 30.000, 25.000 eller 20.000 Daltons; (ii) haren gennemsnitlig numerisk polymeriseringsgrad på 2 til 100, fortrinsvis 2 til 75, 2 til 50, 2 til 35, eller 2 til 30; (iii) er en 3- til 35-mer, 3- til 28-mer, 4- til 25-mer, 6- til 22-mer, 8- til 20-mer, eller 10- til 15-mer; (iv) har mindst 80, 85, 90 eller 95 % G-rester; og/eller (v) har en primær struktur i hvilken mindst 90 % af G-resterne er forbundet 1-4 til en anden G-rest.
5. Alginatoligomer til anvendelse i behandlingen afen biofilminfektion til stede i et individ, hvor alginatoligomeren har mindst 70 % G-rester.
6. Anvendelse afen alginatoligomer i fremstillingen af et lægemiddel til anvendelse i behandlingen af en biofilminfektion til stede i et individ, hvor alginatoligomeren har mindst 70 % G-rester.
7. Alginatoligomeren til anvendelse i behandlingen afen biofilminfektion ifølge krav 5 eller anvendelsen ifølge krav 6, hvor alginatoligomeren (i) har en gennemsnitsmolekylevægt på mindre end 35.000 Daltons, fortrinsvis mindre end 30.000, 25.000 eller 20.000 Daltons; (ii) haren gennemsnitlig numerisk polymeriseringsgrad på 2 til 100, fortrinsvis 2 til 75, 2 til 50, 2 til 35, eller 2 til 30; (iii) er en 3- til 35-mer, 3- til 28-mer, 4- til 25-mer, 6- til 22-mer, 8- til 20-mer, eller 10- til 15-mer; (iv) har mindst 80, 85, 90 eller 95 % G-rester; og/eller (v) har en primær struktur i hvilken mindst 90 % af G-resterne er forbundet 1-4 til en anden G-rest.
8. Alginatoligomeren til anvendelse i behandlingen afen biofilminfektion eller anvendelse ifølge et hvilket som helst af kravene 5 til 7, hvor biofilmen er i eller på en indvendig eller udvendig kropsflade, og fortrinsvis hvor den indvendige eller udvendige kropsflade er valgt fra en overflade i mundhulen, forplantningskanalen, urinvejen, luftvejene, mavetarmkanalen, bughinden, mellemøret, prostata, vaskulær intima, øjets bindehinde, hornhindevæv, lungevæv, hjerteklapper, hud, hovedbund, negle eller det indre af sår.
9. Alginatoligomeren til anvendelse i behandlingen afen biofilminfektion eller anvendelse ifølge et hvilket som helst af kravene 5 til 8, hvor individet er et individ valgt fra et individ med en præetableret infektion, et immunkompromitteret individ, et individ der undergår intensiv eller kritisk behandling, et individ der lider af traume, et individ med et brandsår, et individ med et akut og/eller kronisk sår, et neonatalt individ, et ældre individ, et individ med cancer, et individ der lider af en autoimmun tilstand, et individ med reduceret eller ophørt epithel eller endothelsekretion og/eller sekretions-clearance eller et individ udstyret med en medicinsk indretning, og fortrinsvis hvor individet er valgt fra et individ med en tilstand valgt fra HIV, sepsis, septisk chok, AIDS, en cancer af immunsystemet, rheumatoid arthrit, diabetes mellitus type I, Crohns sygdom, COPD, bronkitis, cystisk fibrose, emfysem, lungecancer, astma, lungebetændelse og bihulebetændelse, et individ der gøres klar til, undergår, eller kommer sig over kemoterapi og/eller strålebehandling, et organtransplantationsindivid, et individ der bosat i en sundhedsplejeinstitution eller en ryger.
10. Alginatoligomeren til anvendelse i behandlingen afen biofilminfektion eller anvendelse ifølge et hvilket som helst af kravene 5 til 9, hvor alginatoligomeren anvendes til at behandle biofilminfektion i sår og/eller brandsår eller i en indlagt medicinsk indretning.
11. Alginatoligomeren til anvendelse i behandlingen afen biofilminfektion eller anvendelse ifølge et hvilket som helst af kravene 5 til 10 hvor alginatoligomeren anvendes i behandlingen af tandplak, gingivitis, periodontitis, nativ ventil endocarditis, akut otitis media, kronisk bakteriel prostatitis, lungebetændelse, astma eller indretnings-relateret infektion associeret med implanterbare og/eller protetiske medicinske indretninger eller vævserstatninger.
12. Fremgangsmåden, alginatoligomertil anvendelse i behandlingen afen biofilminfektion eller anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor alginatoligomeren anvendes i kombination med et antimikrobielt middel, og fortrinsvis hvor det antimikrobielle middel er et antibiotika eller et antisvampemiddel eller et antiseptika, desinfektionsmiddel, steriliserings- eller rengøringsmiddel.
13. Fremgangsmåden, alginatoligomeren til anvendelse i behandlingen afen biofilminfektion eller anvendelse ifølge et hvilket som helst af kravene 1 til 12, hvor alginatoligomeren anvendes i kombination med mindst et andet biofilm nedbrydende middel og/eller slimhinde viskositet-reducerende middel, fortrinsvis valgt fra proteaser, nukleaser, lipaser, enzymer i stand til at nedbryde polysaccharider, gelsolin, thiolreducerende midler, en acetylcystein, natriumchlorid, eller en anionisk polyaminosyre, og en nitrogenoxid prækursor eller syntesestimulator, og i særdeleshed hvor alginatoligomeren anvendes i kombination med en alginatlyase og/eller et DNase-enzym.
14. Fremgangsmåden, alginatoligomer til anvendelse i behandlingen afen biofilminfektion, eller anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor alginatoligomeren anvendes i kombination med et yderligere terapeutisk aktivt middel, fortrinsvis et immunstimulatorisk middel, en vækstfaktor eller et antiinflammatorisk middel.
15. Produkt indeholdende en alginatoligomer som defineret ifølge et hvilket som helst af kravene 1, 4 eller 7 og et andet aktivt middel som et kombineret præparat til separat, simultan eller sekventiel anvendelse i behandling af biofilminfektion til stede i et individ, fortrinsvis hvor det aktive middel er som defineret i et hvilket som helst af kravene 12 til 14.
16. Produktet ifølge krav 15 i form afen hypertonisk saltvandsopløsning, en inhalerbar opløsning, et inhalerbart pulver, en næsespray, en débridementsammensætning, en topikalsammensætning, en tandpasta eller en mundskyl.
17. Implanterbar medicinsk indretning omfattende en ikke-levende overflade der er belagt med en alginatoligomer som defineret i et hvilket som helst af kravene 1, 4 eller 7.
18. Steril vandig sårdébridementopløsning eller en steril oliebaseret sårdébridementopløsning indeholdende en alginatoligomer som defineret i et hvilket som helst af kravene 1, 4 eller 7 og yderligere indeholdende mindst et proteolytisk enzym og/eller mindst en abrasiv faststoffase, hvor sammensætningen er en steril vandig opløsning eller en steril oliebaseret opløsning.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99661107P | 2007-11-27 | 2007-11-27 | |
PCT/GB2008/003607 WO2009068841A2 (en) | 2007-11-27 | 2008-10-24 | Use of alginate oligomers in combating biofilms |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2268142T3 true DK2268142T3 (da) | 2017-05-22 |
Family
ID=40527942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08875658.0T DK2268142T3 (da) | 2007-11-27 | 2008-10-24 | Anvendelse af alginerede oligomerer til at bekæmpe biofilm |
Country Status (17)
Country | Link |
---|---|
US (3) | US8680072B2 (da) |
EP (1) | EP2268142B1 (da) |
JP (2) | JP5639475B2 (da) |
KR (1) | KR101690631B1 (da) |
CN (3) | CN107050047B (da) |
AU (1) | AU2008328567B2 (da) |
BR (1) | BRPI0819613B1 (da) |
CA (1) | CA2706637C (da) |
DK (1) | DK2268142T3 (da) |
ES (1) | ES2625866T3 (da) |
HU (1) | HUE034051T2 (da) |
PL (1) | PL2268142T3 (da) |
PT (1) | PT2268142T (da) |
RS (1) | RS55933B1 (da) |
RU (1) | RU2527894C2 (da) |
SI (1) | SI2268142T1 (da) |
WO (1) | WO2009068841A2 (da) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
CA2706637C (en) | 2007-11-27 | 2016-11-29 | Algipharma Ipr As | Use of alginate oligomers in combating biofilms |
GB0909529D0 (en) * | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Alginate oligomers for the inhibition of microbial adherence to surfaces |
PT2437783E (pt) | 2009-06-03 | 2014-01-22 | Algipharma As | Tratamento de acinetobacter com oligómeros de alginato e antibióticos |
GB0909557D0 (en) * | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Anti-microbial alginate oligomers |
GB2477914B (en) | 2010-02-12 | 2012-01-04 | Univ Newcastle | Compounds and methods for biofilm disruption and prevention |
US9572774B2 (en) | 2011-05-19 | 2017-02-21 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
GB201116010D0 (en) * | 2011-09-15 | 2011-10-26 | Algipharma As | Use of alginate oligomers to enhance the effects of antifungal agents |
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
EP2849777B1 (en) | 2012-05-11 | 2017-10-18 | Smith & Nephew, Inc. | Seaprose for removing bacterial biofilm |
GB201208879D0 (en) * | 2012-05-21 | 2012-07-04 | London School Hygiene & Tropical Medicine | Therapeutic for treating Clostridium difficile infection |
US9546361B2 (en) * | 2012-10-12 | 2017-01-17 | Lehigh University | Thermally stable enzymes, compositions thereof and methods of using same |
AU2012321097B2 (en) | 2012-12-25 | 2016-06-30 | The University Of Melbourne | Materials and methods |
KR101438969B1 (ko) * | 2012-12-27 | 2014-09-11 | 현대자동차주식회사 | 무취 에바코어 코팅용 미생물 슈도모나스 나이트로리듀센스 및 이의 용도 |
WO2015038731A1 (en) * | 2013-09-12 | 2015-03-19 | The Johns Hopkins University | Biofilm formation to define risk for colon cancer |
GB201322777D0 (en) * | 2013-12-20 | 2014-02-05 | Algipharma As | Use of alginate oligomers as blood anticoagulants |
JP2017501221A (ja) * | 2013-12-23 | 2017-01-12 | ノルウェージャン ユニバーシティ オブ サイエンス アンド テクノロジー(エヌティーエヌユー) | がん治療におけるオリゴウロン酸塩の使用 |
EP3110426A1 (en) * | 2014-02-28 | 2017-01-04 | Algipharma As | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
RU2737535C2 (ru) * | 2014-04-11 | 2020-12-01 | Новозимс А/С | Моющая композиция |
FR3024358B1 (fr) * | 2014-08-01 | 2017-11-10 | Soc De Courtage Et De Diffusion Codif Int | Compositions cosmetiques et complements alimentaires neuro-protecteurs comprenant de l'oligoalginate ayant un degre de polymerisation de 10 pour lutter contre le vieillissement de la peau. |
GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
GB201504878D0 (en) * | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
AU2016338586B2 (en) * | 2015-10-12 | 2021-01-28 | Amsilk Gmbh | Use of a biopolymer for reducing the formation of a biofilm |
RU2646488C2 (ru) * | 2016-04-25 | 2018-03-05 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОрГМУ Минздрава России) | Средство для селективного влияния на биопленкообразование микроорганизмами |
EP3490588A1 (en) * | 2016-07-27 | 2019-06-05 | Smith&Nephew, Inc. | Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces |
WO2018064284A1 (en) | 2016-09-30 | 2018-04-05 | Novaflux, Inc. | Compositions for cleaning and decontamination |
GB2555391B (en) * | 2016-10-21 | 2019-06-26 | Algipharma As | Bacitracin-alginate oligomer conjugates |
KR20190072579A (ko) * | 2016-10-21 | 2019-06-25 | 알지파마 에이에스 | 폴리믹신-알기네이트 올리고머 콘주게이트 |
JP6927512B2 (ja) * | 2016-10-26 | 2021-09-01 | 地方独立行政法人神奈川県立産業技術総合研究所 | 物体表面の抗菌性試験用菌液媒体 |
WO2018127819A1 (en) | 2017-01-03 | 2018-07-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
WO2018140707A1 (en) | 2017-01-30 | 2018-08-02 | Smith & Nephew, Inc. | Synergistic combination of thermolysin and an antibacterial agent to reduce eliminate bacterial biofilms from surfaces |
EP3600338A4 (en) | 2017-03-28 | 2020-10-28 | The University of North Carolina at Chapel Hill | NITRIC OXIDE RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES |
JP2021515083A (ja) | 2018-03-06 | 2021-06-17 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill | 生分解性の抗菌性足場としての一酸化窒素放出性シクロデキストリンおよびそれに関する方法 |
US11345878B2 (en) | 2018-04-03 | 2022-05-31 | Novaflux Inc. | Cleaning composition with superabsorbent polymer |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
GB201812473D0 (en) | 2018-07-31 | 2018-09-12 | Algipharma As | Method for the qualitative and quantitative detection of alginate oligomers in body fluids |
US20220062146A1 (en) * | 2018-12-17 | 2022-03-03 | Dennis C. Mynarcik | Compositions and methods for removing dental calculi |
CN109431962B (zh) * | 2018-12-19 | 2021-10-29 | 仙婷(广州)科技研发有限公司 | 一种浮游生物代谢物和浮游生物发酵液及其应用 |
CA3124673A1 (en) | 2018-12-28 | 2020-07-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
US20220306968A1 (en) | 2019-06-06 | 2022-09-29 | Danisco Us Inc | Methods and compositions for cleaning |
GB201908639D0 (en) | 2019-06-17 | 2019-07-31 | Algipharma Ipr As | Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure |
JP7273983B2 (ja) * | 2019-09-27 | 2023-05-15 | 森永乳業株式会社 | 酪酸菌用プレバイオティクス組成物 |
AU2020358982A1 (en) | 2019-10-03 | 2022-04-28 | Novaflux Inc. | Oral cavity cleaning composition, method, and apparatus |
KR102450964B1 (ko) * | 2020-04-27 | 2022-10-05 | 경희대학교 산학협력단 | 아세타니솔을 포함하는 바이오필름 형성 억제용 조성물 |
RU2759744C1 (ru) * | 2020-09-07 | 2021-11-17 | Олег Владимирович Емшанов | Способ борьбы с биологическими плёнками |
KR102566917B1 (ko) * | 2021-03-16 | 2023-08-14 | 영남대학교 산학협력단 | 쏘팔메토 오일 및 이의 불포화 지방산을 유효성분으로 함유하는 다중 병원성 미생물 바이오필름 형성 억제용 조성물 |
CN117916354A (zh) | 2021-09-03 | 2024-04-19 | 丹尼斯科美国公司 | 用于清洁的衣物洗涤组合物 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE268865C (da) | ||||
US1234567A (en) * | 1915-09-14 | 1917-07-24 | Edward J Quigley | Soft collar. |
NL297511A (da) | 1956-12-20 | |||
FR7576M (da) | 1968-03-27 | 1970-01-05 | ||
HU172831B (hu) | 1976-03-31 | 1978-12-28 | Egyt Gyogyszervegyeszeti Gyar | Sposob poluchenija kompleksov oligo- i poligalakturonnyk kislot s ionami zhiznenno vazhnykh metallov |
JPH0714842B2 (ja) * | 1985-12-11 | 1995-02-22 | ダイセル化学工業株式会社 | 防かび殺菌方法 |
DD268865A1 (de) | 1987-01-16 | 1989-06-14 | Adw Ddr | Verfahren zur herstellung eines pharmazeutischen praeparates |
US4898852A (en) | 1987-06-02 | 1990-02-06 | Walsh William E | Cyclopolgalcturonic acid composition and treatment |
US4855128A (en) * | 1988-01-14 | 1989-08-08 | Warner-Lambert Company | Saccharide inhibition of dental plaque |
GB8803157D0 (en) | 1988-02-11 | 1988-03-09 | Nat Res Dev | Denture protection |
US5139945A (en) * | 1988-09-16 | 1992-08-18 | Novo Industri A/S | Thermostable alginate lyase from bacillus steraothermophilus |
WO1991011205A1 (en) | 1990-01-23 | 1991-08-08 | Trancel Corporation | Mannuronic acid containing alginate wound healing composition and method |
JPH0436228A (ja) * | 1990-05-30 | 1992-02-06 | Lion Corp | 口腔用組成物 |
CN1021798C (zh) | 1990-12-19 | 1993-08-18 | 大连市医药科学研究所 | 净癣涂膜剂制备工艺 |
US5169840A (en) * | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
US5166137A (en) | 1991-03-27 | 1992-11-24 | Nobipols Forskningsstiftelse | Guluronic acid polymers and use of same for inhibition of cytokine production |
JPH05252970A (ja) | 1991-10-04 | 1993-10-05 | Maruha Corp | 静菌作用を有するアルギン酸オリゴ糖の製造法及 びそれを有効成分として含む静菌剤 |
CA2106609A1 (en) | 1992-09-28 | 1994-03-29 | Irene Yeatman Aldridge | Proteases to inhibit and remove biofilm |
GB9221163D0 (en) | 1992-10-08 | 1992-11-25 | Nobipol And Protan Biopolymer | Dna compounds |
DE4330773A1 (de) | 1993-09-10 | 1995-03-16 | Laevosan Gmbh & Co Kg | Blockierung der Anlagerung von Keimen an menschliche Zellen |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
JPH093031A (ja) | 1995-04-17 | 1997-01-07 | Mitsubishi Chem Corp | ヒドロキサム酸誘導体並びにそれを含有する農園芸用殺菌剤 |
DE69637625D1 (de) | 1995-10-19 | 2008-09-18 | Bio Origyn Llc | Methoden und zusammensetzungen, die das ueberleben und die funktion von keimbahnzellen und embryonen verbessern |
JP3512553B2 (ja) | 1996-01-30 | 2004-03-29 | ポーラ化成工業株式会社 | 便秘抑制剤及びそれを含有する組成物 |
GB9605247D0 (en) * | 1996-03-13 | 1996-05-15 | Giltech Ltd | Composition |
EP0807631B1 (en) | 1996-05-15 | 2003-03-12 | Sankyo Company Limited | Tricyclic compounds having fungicidal activity, their preparation and their use |
NO305441B1 (no) * | 1996-07-12 | 1999-05-31 | Norsk Hydro As | Anvendelse av G-blokk polysakkarider |
JPH10127281A (ja) * | 1996-10-31 | 1998-05-19 | Tanabe Seiyaku Co Ltd | Peg修飾アルギン酸リアーゼおよびその用途 |
CN1197584C (zh) * | 1997-04-30 | 2005-04-20 | 雷克特本克斯尔保健(英国)有限公司 | 可倾倒的藻酸盐组合物 |
NO305033B1 (no) | 1997-05-09 | 1999-03-22 | Algipharma As | Fremgangsmate for fremstilling av uronsyreblokker fra alginat |
GB2325233B (en) | 1997-05-16 | 2001-07-18 | Norsk Hydro As | Substrates having bound polysaccharides and bacterial nucleic acids |
US6339075B1 (en) | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
AU9374298A (en) | 1997-09-12 | 1999-04-05 | Oceanix Biosciences Corporation | Preparation and use of biofilm-degrading, multiple-specificit y, hydrolytic enzyme mixtures |
US6830745B1 (en) * | 1997-10-16 | 2004-12-14 | Pharmacal Biotechnologies, Llc | Compositions for treating biofilm |
US20020022005A1 (en) * | 1997-10-16 | 2002-02-21 | Budny John A. | Compositions for treating cystic fibrosis |
JP2000063208A (ja) * | 1998-08-20 | 2000-02-29 | Daicel Chem Ind Ltd | 抗菌性組成物 |
KR100322511B1 (ko) | 1998-11-13 | 2002-10-25 | 한국해양연구원 | 알긴산 올리고당 유도체를 이용한 적조소멸제 및 어병치료제 |
EP1212047A2 (en) | 1999-08-26 | 2002-06-12 | The Governors Of The University Of Alberta | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
US20040224922A1 (en) | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
AU7434200A (en) * | 1999-09-23 | 2001-04-24 | Reckitt Benckiser (Uk) Limited | Method for combating hard water and scale by using algins |
DE10006989A1 (de) * | 2000-02-16 | 2001-08-23 | Nutricia Nv | Antiadhäsive Kohlenhydratmischung |
RU2274442C2 (ru) | 2000-03-07 | 2006-04-20 | Раш-Презбитериан-Ст. Лук'С Медикал Сентер | Композиции и способы улавливания и инактивации патогенных микроорганизмов и сперматозоидов |
GB0005743D0 (en) * | 2000-03-10 | 2000-05-03 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions including alginates |
DE10019076A1 (de) | 2000-04-06 | 2001-10-18 | Lang Christine | Verwendung von Polygalakturoniden als Lebensmittelzusatzstoffe |
IL156596A0 (en) | 2000-12-27 | 2004-01-04 | Salus Pharma Inc | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |
ITMI20010347A1 (it) | 2001-02-21 | 2002-08-21 | Grisotech S A | Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale |
US7494669B2 (en) | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
JP2002315551A (ja) * | 2001-04-19 | 2002-10-29 | Yoshinaga Nakai | 食品用防腐剤およびその製造方法 |
NO326145B1 (no) | 2001-11-30 | 2008-10-06 | Fmc Biopolymer As | Fremgangsmate for a stimulere vektokning hos pattedyr, fugler og krypdyr. |
NO324131B1 (no) | 2001-11-30 | 2007-09-03 | Fmc Biopolymer As | Fremgangsmate for fremstilling av alginat som har et hoyt mannuronsyre-innhold |
WO2003059302A1 (en) * | 2002-01-03 | 2003-07-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Edible compositions capable of removing oral biofilm |
DE10221748B4 (de) | 2002-05-16 | 2006-08-10 | Kaczmarek, André, Dr.med.dent. | Antimykotisches Haftpulver gegen Prothesenstomatitis, die Herstellung und Verabreichungsform |
US6610331B1 (en) | 2002-05-30 | 2003-08-26 | Scott M. Sweazy | Fertility kit |
NO20023581D0 (no) | 2002-07-26 | 2002-07-26 | Fmc Biopolymer As | Nye mutantstammer av Pseudomonas fluorescens og varianter derav, metoder for produksjon og bruk derav til produksjon avalginat |
US20070237812A1 (en) | 2006-04-11 | 2007-10-11 | Tyco Healthcare Group | Multi-layer wound dressings |
GB0300597D0 (en) * | 2003-01-10 | 2003-02-12 | Microbiological Res Authority | Phage biofilms |
DE602004025824D1 (de) * | 2003-09-08 | 2010-04-15 | Fmc Biopolymer As | Gel-schaum auf biopolymer-basis |
CA2540104A1 (en) | 2003-09-30 | 2005-04-07 | Solubest Ltd. | Water soluble nanoparticles comprising inclusion complexes |
JP2005145885A (ja) | 2003-11-14 | 2005-06-09 | Japan Science & Technology Agency | アルギン酸オリゴマーからなる免疫機構賦活剤 |
CN101001635A (zh) | 2003-12-04 | 2007-07-18 | 生物膜策略公司 | 预防生物膜形成、减少现有生物膜和减少细菌群的方法和组合物 |
CN1921833A (zh) * | 2004-02-26 | 2007-02-28 | 博士伦公司 | 藻酸盐粘弹性组合物、使用方法及包装 |
JP5367266B2 (ja) * | 2004-10-12 | 2013-12-11 | エフエムシー バイオポリマー エイエス | 自己ゲル化性アルギネート系及びその使用 |
EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
EP1879589A2 (en) | 2005-05-13 | 2008-01-23 | Venus Remedies Limited | Treatment and control of severe infections including cystic fibrosis |
EP1745705A1 (en) | 2005-07-20 | 2007-01-24 | N.V. Nutricia | Process for preparing uronic acid oligosaccharides by extrusion |
GB2430881B (en) | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
JP5110860B2 (ja) * | 2006-11-30 | 2012-12-26 | 花王株式会社 | バイオフィルム制御剤組成物 |
EP1872791A1 (en) | 2006-06-30 | 2008-01-02 | Institut Pasteur | Use of bacterial polysaccharides for biofilm inhibition |
JP5248492B2 (ja) | 2006-07-14 | 2013-07-31 | エフエムシー バイオポリマー エイエス | 低分子量アルギネートを含むヒドロゲルおよびそれから製造されたバイオ構造物 |
DE102006059510A1 (de) | 2006-12-14 | 2008-06-19 | Grünenthal GmbH | Beschichtete Pellets |
WO2008082948A2 (en) | 2006-12-29 | 2008-07-10 | Bausch & Lomb Incorporated | Ophthalmic alginate composition related methods of manufacture and methods of use |
EP2526928B1 (en) | 2007-02-05 | 2018-12-26 | Biophile Corporation, Ltd | Increased effectiveness of allylamine drug compounds |
GB0707096D0 (en) | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
JP2008285431A (ja) | 2007-05-16 | 2008-11-27 | Japan Science & Technology Agency | 養殖魚のウイルス感染症の予防・治療組成物 |
US20090036554A1 (en) | 2007-08-01 | 2009-02-05 | Burke Susan E | Ophthalmic compositions comprising a terpene compound |
US20090036404A1 (en) | 2007-08-02 | 2009-02-05 | Macleod Steven K | Ophthalmic compositions comprising a carboxyl-modified fructan or a salt thereof |
CA2706637C (en) * | 2007-11-27 | 2016-11-29 | Algipharma Ipr As | Use of alginate oligomers in combating biofilms |
US20110076240A1 (en) | 2008-04-18 | 2011-03-31 | Day Donal F | Antifungal and Anti-Cariogenic Cellobio-Oligosaccharides Produced by Dextransucrase |
WO2010069519A1 (en) | 2008-12-18 | 2010-06-24 | Merz Pharma Gmbh & Co. Kgaa | Topical compositions comprising at least one active ingredient poorly soluble in water and biopolymers such as hyaluronic acid with a pka-value between 5-7 |
PT2437783E (pt) * | 2009-06-03 | 2014-01-22 | Algipharma As | Tratamento de acinetobacter com oligómeros de alginato e antibióticos |
GB0909529D0 (en) | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Alginate oligomers for the inhibition of microbial adherence to surfaces |
-
2008
- 2008-10-24 CA CA2706637A patent/CA2706637C/en active Active
- 2008-10-24 PL PL08875658T patent/PL2268142T3/pl unknown
- 2008-10-24 CN CN201611042352.9A patent/CN107050047B/zh active Active
- 2008-10-24 RS RS20170466A patent/RS55933B1/sr unknown
- 2008-10-24 RU RU2010120766/10A patent/RU2527894C2/ru active
- 2008-10-24 JP JP2010534533A patent/JP5639475B2/ja active Active
- 2008-10-24 PT PT88756580T patent/PT2268142T/pt unknown
- 2008-10-24 HU HUE08875658A patent/HUE034051T2/en unknown
- 2008-10-24 AU AU2008328567A patent/AU2008328567B2/en active Active
- 2008-10-24 SI SI200831807T patent/SI2268142T1/sl unknown
- 2008-10-24 CN CN200880118093.0A patent/CN101939030B/zh active Active
- 2008-10-24 KR KR1020107014146A patent/KR101690631B1/ko active IP Right Grant
- 2008-10-24 US US12/745,058 patent/US8680072B2/en active Active
- 2008-10-24 EP EP08875658.0A patent/EP2268142B1/en active Active
- 2008-10-24 ES ES08875658.0T patent/ES2625866T3/es active Active
- 2008-10-24 BR BRPI0819613A patent/BRPI0819613B1/pt not_active IP Right Cessation
- 2008-10-24 CN CN201410399745.XA patent/CN104189908B/zh active Active
- 2008-10-24 DK DK08875658.0T patent/DK2268142T3/da active
- 2008-10-24 WO PCT/GB2008/003607 patent/WO2009068841A2/en active Application Filing
-
2014
- 2014-03-21 US US14/221,691 patent/US9877983B2/en active Active
- 2014-10-23 JP JP2014216271A patent/JP6014101B2/ja active Active
-
2017
- 2017-12-04 US US15/831,221 patent/US10624920B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10624920B2 (en) | Use of alginate oligomers in combating biofilms | |
EP2437783B1 (en) | Treatment of acinetobacter with alginate oligomers and antibiotics | |
WO2010139959A2 (en) | Alginate oligomers for the inhibition of microbial adherence to surfaces | |
WO2010139958A1 (en) | Anti-microbial alginate oligomers |